cisapride has been researched along with Indigestion in 139 studies
Cisapride: A substituted benzamide used for its prokinetic properties. It is used in the management of gastroesophageal reflux disease, functional dyspepsia, and other disorders associated with impaired gastrointestinal motility. (Martindale The Extra Pharmacopoeia, 31st ed)
cisapride : The amide resulting from formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with cis-1-[3-(4-fluorophenoxy)propyl]-3-methoxypiperidin-4-amine. It has been used (as its monohydrate or as its tartrate) for the treatment of gastro-oesophageal reflux disease and for non-ulcer dyspepsia, but its propensity to cause cardiac arrhythmias resulted in its complete withdrawal from many countries, including the U.K., and restrictions on its use elsewhere.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aim of the study is to compare the clinical efficacy of levosulpiride and cisapride in patients with dysmotility-like functional dyspepsia." | 9.11 | Levosulpiride and cisapride in the treatment of dysmotility-like functional dyspepsia: a randomized, double-masked trial. ( Balboa, A; Jiménez, I; Mearin, F; Patón, C; Pérez-Mota, A; Rodrigo, L; Sebastián, JJ, 2004) |
| " pylori infection has an effect on the improvement of dyspeptic symptoms in response to a prokinetic agent, cisapride, in patients with non-ulcer dyspepsia (NUD)." | 9.11 | Lack of effect of Helicobacter pylori on symptom improvement with a prokinetic medication, cisapride, in patients with non-ulcer dyspepsia. ( Chaiwatanarat, T; Gonlachanvit, S; Kullavanijaya, P; Mahachai, V, 2005) |
| "To investigate whether cisapride accelerates gastric emptying in the long term or improves diabetes control in patients with diabetic gastroparesis." | 9.10 | Long-term cisapride treatment improves diabetic gastroparesis but not glycaemic control. ( Braden, B; Caspary, WF; Enghofer, M; Lembcke, B; Schaub, M; Usadel, KH, 2002) |
| "To compare the efficacy of simethicone with placebo and the prokinetic cisapride in patients with functional dyspepsia." | 9.10 | A randomized placebo-controlled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia. ( Gschossmann, J; Holtmann, G; Mayr, P; Talley, NJ, 2002) |
| "To compare the efficacy of the herbal preparation STW 5 (Iberogast ((R))) and the research preparation STW 5-II with cisapride for treatment of patients with dysmotility type of functional dyspepsia." | 9.10 | A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia. ( Rösch, W; Sassin, I; Vinson, B, 2002) |
| "To compare the efficacy of simethicone with cisapride in patients with functional (non-ulcer) dyspepsia." | 9.09 | Randomised double-blind comparison of simethicone with cisapride in functional dyspepsia. ( Becker, B; Fischer, T; Gerken, G; Gschossmann, J; Holtmann, G; Karaus, M; Mayr, P, 1999) |
| "To compare the effects of chronic oral administration of cisapride and levosulpiride in patients with functional dyspepsia and delayed gastric emptying." | 9.09 | Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis. ( Biagini, R; Borro, P; Giacomini, M; Mansi, C; Mele, MR; Pandolfo, N; Savarino, V, 2000) |
| "Cisapride provides symptomatic relief and improves gastric myoelectrical abnormalities in patients with functional dyspepsia." | 9.09 | Cisapride provides symptomatic relief in functional dyspepsia associated with gastric myoelectrical abnormality. ( Chen, JD; Ke, MY; Lin, XM; Wang, Z; Zhang, M, 2000) |
| "The aim of this study was to compare symptoms for patients with uninvestigated dyspepsia and a negative Helicobacter pylori serology who were treated with cisapride or placebo." | 9.09 | Treatment of uninvestigated dyspepsia with cisapride for patients with negative Helicobacter pylori serologies. ( Avins, AL; Kearney, DJ; McQuaid, KR, 2000) |
| "To assess the efficacy of cisapride therapy in relieving symptoms of functional dyspepsia." | 9.08 | Efficacy of cisapride therapy in functional dyspepsia. ( Cowan, H; Eckstein, RP; Höschl, R; Kellow, JE; Lam, SK; Lunzer, MR; Riley, JW; Shuter, B, 1995) |
| "Cisapride and ranitidine improved the symptoms of diffuse epigastric pain, postprandial epigastric fullness, epigastric distension, belching, heartburn, regurgitation, and nausea when compared with baseline." | 9.08 | Cisapride compared with ranitidine in the treatment of functional dyspepsia. ( Carvalhinhos, A; Fidalgo, P; Freire, A; Matos, L, 1995) |
| "A controlled multi-centre clinical trial was conducted for evaluating the efficacy and safety of cisapride in the treatment of 414 cases of functional dyspepsia with 169 cases as control." | 9.08 | [A controlled multi-centre clinical trial on cisapride in treatment of functional dyspepsia]. ( Jia, B; Liang, X; Wang, B, 1995) |
| "Little is known about the prescribing habits and impact of life style or disease factors on the outcome of cisapride treatment for dyspepsia in primary care." | 9.08 | Factors affecting dose selection and outcome of cisapride treatment for dyspepsia in primary care. The Austro-Cis Study Group. ( Brunner, H, 1996) |
| "In the present double-blind placebo-controlled study the effect of cisapride on functional dyspepsia was evaluated in patients with and without histological gastritis." | 9.08 | Effect of cisapride on functional dyspepsia in patients with and without histological gastritis: a double-blind placebo-controlled trial. ( Chintana-Wilde, W; Choo, HF; Gwee, KA; Kang, JY; Tan, CC; Tay, HH; Teh, M; Wee, A; Yeoh, KG, 1997) |
| "The effects of a 2-wk course of cisapride or nizatidine in unselected patients with dyspepsia recruited from primary care were not superior to those of placebo." | 9.08 | Placebo-controlled trial of cisapride and nizatidine in unselected patients with functional dyspepsia. ( Bytzer, P; Hansen, JM; Schaffalitzky de Muckadell, OB, 1998) |
| " All patients completed a dyspepsia symptom questionnaire and were then treated with cisapride 10 mg t." | 9.08 | The effect of cisapride on dyspepsia symptoms and the electrogastrogram in patients with non-ulcer dyspepsia. ( Besherdas, K; Epstein, O; Harbord, M; Leahy, A; Mason, I, 1998) |
| "To test the effect of cisapride on symptom score and on fasting and postprandial antral area in patients with dysmotility-like functional dyspepsia compared with controls." | 9.08 | The effect of cisapride on dysmotility-like functional dyspepsia: reduction of the fasting and postprandial area, but not of the postprandial antral expansion. ( Barnert, J; Dumitrascu, DL; Eberl, T; Fischer, J; Wienbeck, M, 1998) |
| "The efficacy and tolerability of cisapride (5 mg three times daily) and metoclopramide (10 mg three times daily) were evaluated in a randomized double-blind trial in patients with functional dyspepsia." | 9.07 | Cisapride versus metoclopramide in the treatment of functional dyspepsia. A double-blind comparative trial. ( Fumagalli, I; Hammer, B, 1994) |
| "The efficacy and tolerability of Cisapride effervescent granules and a metoclopramide-dimethicone combination were compared double-blind in two comparable groups of 15 patients each with dyspepsia." | 9.07 | [Efficacy and tolerability of cisapride in a new formula of 10 mg effervescent capsules for the treatment of functional dyspepsia]. ( Di Felice, F; Grossi, L; Marzio, L, 1993) |
| "Twenty patients with functional dyspepsia were referred for radiologic examination and, upon confirmation of a hypomotile stomach, were given either 10 mg cisapride or placebo in a double-blind manner (10 patients per group)." | 9.07 | A double-blind fluoroscopic study of cisapride on gastrointestinal motility in patients with functional dyspepsia. ( De Schepper, A; Degryse, H; Verlinden, M, 1993) |
| "The efficacy and tolerability of cisapride in chronic dyspepsia was evaluated in a randomized, double-blind, placebo-controlled study." | 9.07 | Cisapride in chronic dyspepsia: results of a double-blind, placebo-controlled trial. ( Chung, JM, 1993) |
| "A double-blind, placebo-controlled trial was performed to determine the therapeutic efficacy of cisapride in patients with refractory functional dyspepsia." | 9.07 | Efficacy of cisapride in functional dyspepsia resistant to domperidone or metoclopramide: a double-blind, placebo-controlled study. ( De Nutte, N; Gooris, JP; Van Eeghem, P; Van Outryve, M, 1993) |
| "One hundred and twenty consecutive outpatients with non-ulcer dyspepsia (NUD) and erosive prepyloric changes (EPC) were, after a 2-week placebo run-in period, randomly allocated to double-blind treatment with either 10-mg cisapride tablets or placebo three times daily for 4 weeks." | 9.07 | Cisapride treatment of patients with non-ulcer dyspepsia and erosive prepyloric changes. A double-blind, placebo-controlled trial. ( Berstad, A; Hausken, T, 1992) |
| "Fasting antral area was examined by ultrasonography in 40 healthy subjects and in 106 patients with non-ulcer dyspepsia (NUD) and erosive prepyloric changes (EPC) before and after treatment with cisapride or placebo." | 9.07 | Wide gastric antrum in patients with non-ulcer dyspepsia. Effect of cisapride. ( Berstad, A; Hausken, T, 1992) |
| "Controlled studies showed that cisapride is effective in non-ulcer dyspepsia." | 9.07 | [Cisapride: clinical experience in 1071 patients with non-ulcer dyspepsia or reflux symptoms]. ( Fehr, HF, 1991) |
| "In a randomized, double-blind, placebo-controlled study, 32 patients with nonulcer dyspepsia received 5 mg of cisapride or placebo three times daily for four weeks after a two-week run-in phase on placebo." | 9.06 | Relief of epigastric pain in nonulcer dyspepsia: controlled trial of the promotility drug cisapride. ( De Nutte, N; Defrance, P; Van Ganse, W; Witterhulghe, M, 1989) |
| " It was the aim of this study to assess the acute effects of cisapride on antroduodenal motility and duodenogastric reflux in seven patients with severe dyspepsia and increased biliary reflux, as evidenced by increased bile salt output in their gastric aspirates." | 9.06 | Cisapride stimulates antral motility and decreases biliary reflux in patients with severe dyspepsia. ( Di Lorenzo, C; Dooley, CP; Rezende-Filho, J; Valenzuela, JE, 1989) |
| "The effects of cisapride, a nondopaminolytic motility-enhancing agent, were studied in 56 patients with chronic functional dyspepsia; all had symptoms suggestive of delayed gastric emptying." | 9.06 | Cisapride in the management of chronic functional dyspepsia: a multicenter, double-blind, placebo-controlled study. ( Deruyttere, M; Heylen, H; Lepoutre, L; Pennoit, H; Samain, H, 1987) |
| "The effect of cisapride, 10 mg three times daily, was evaluated in a double-blind randomized study in 118 patients with non-ulcer dyspepsia." | 9.06 | Cisapride in non-ulcer dyspepsia. Results of a placebo-controlled trial. ( Rösch, W, 1987) |
| "Evidence for the effectiveness of antacids, histamine-2 receptor antagonists, bismuth salts, sucralfate and prokinetic therapy in non-ulcer dyspepsia is conflicting." | 8.82 | Systematic review: Antacids, H2-receptor antagonists, prokinetics, bismuth and sucralfate therapy for non-ulcer dyspepsia. ( Deeks, J; Delaney, B; Forman, D; Harris, A; Innes, M; Moayyedi, P; Soo, S, 2003) |
| "Both cisapride and domperidone seem to be efficacious in functional dyspepsia, although this conclusion is largely based on global assessment by the investigator, which may not be an optimal outcome measure." | 8.81 | Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. ( Jones, MJ; Talley, NJ; Veldhuyzen van Zanten, SJ; Verlinden, M, 2001) |
| "Non-ulcer dyspepsia is gaining increasing interest among gastroenterologists even though the pathogenetic mechanisms in individual patients are still unknown." | 7.76 | Efficacy of cisapride in the treatment of epigastric pain and concomitant symptoms in non-ulcer dyspepsia. ( Rösch, W, 1989) |
| "We examined the effect of oral cisapride on gastric emptying time and myoelectrical activity using real-time ultrasonography and cutaneous electrogastrography in 10 children with nonulcer dyspepsia." | 7.69 | Gastric emptying and myoelectrical activity in children with nonulcer dyspepsia. Effect of cisapride. ( Chiloiro, M; Cucchiara, S; Giorgio, I; Guerra, V; Minella, R; Riezzo, G, 1995) |
| "Gastric emptying in 14 patients with chronic hepatitis C was estimated by the sulfamethizole capsule method before and 1 and 2 weeks after the beginning of interferon-alpha (6 million U/day) therapy." | 7.69 | Delayed gastric emptying during interferon-alpha therapy in patients with chronic hepatitis C: relief by cisapride. ( Kanayama, S; Kawata, S; Matsuzawa, Y; Nishibayashi, H; Shinomura, Y, 1997) |
| "An open prospective drug monitoring study was undertaken to assess the efficacy and tolerability of 5 mg cisapride three times daily in 37,925 general practice patients with functional dyspepsia." | 7.68 | A German drug-monitoring study in general practice patients receiving cisapride for functional dyspepsia. ( Liehr, H; Schmidt, R, 1993) |
| "Treatment with omeprazole provides superior symptom relief compared to ranitidine, cisapride, and placebo in the treatment of H." | 6.71 | A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study. ( Armstrong, D; Barkun, A; Chiba, N; Escobedo, S; Lee, J; Sinclair, P; Smyth, S; Thomson, A; Veldhuyzen van Zanten, SJ, 2005) |
| "Treatment with cisapride increased sympathetic tone in the patient group but had no effect on vagal tone." | 6.69 | Effect of mental stress and cisapride on autonomic nerve functions in functional dyspepsia. ( Berstad, A; Hausken, T; Hveem, K; Svebak, S, 1998) |
| "Cisapride is an effective and well-tolerated treatment for FD in Saudi Arabs." | 6.68 | A double-blind, randomized, placebo-controlled trial of cisapride in Saudi Arabs with functional dyspepsia. ( al-Quorain, A; al-Shedoki, F; Larbi, EB, 1995) |
| "Functional dyspepsia is recognized as a common disorder in clinical practice." | 6.68 | Cisapride in functional dyspepsia in general practice. A placebo-controlled, randomized, double-blind study. ( de Both, PS; de Groot, GH, 1997) |
| "Cisapride is a substituted benzamide with gastrointestinal prokinetic effects presumed to be due to the enhancement of the physiological release of acetylcholine at the myenteric plexus." | 6.68 | A double-blind randomized study of cisapride in the treatment of nonulcer dyspepsia. The Canadian Cisapride Nud Study Group. ( Archambault, A; Champion, MC; Eberhard, S; MacCannell, KL; Sullivan, SN; Tanton, R; Thomson, AB, 1997) |
| "Cisapride was more effective than domperidone in the REFLUX-Group." | 6.68 | Study with two prokinetics in functional dyspepsia and GORD: domperidone vs. cisapride. ( Guyot, J; Halter, F; Hammer, B; Miazza, BM; Staub, P, 1997) |
| "Functional dyspepsia is a major diagnostic and therapeutic challenge for the clinician." | 6.67 | Cisapride or cimetidine in the treatment of functional dyspepsia. Results of a double-blind, randomized, Swiss multicentre study. ( Brignoli, R; Halter, F; Miazza, B, 1994) |
| "Cisapride was well tolerated." | 6.67 | Cisapride in functional dyspepsia: a double-blind, placebo-controlled randomized trial in general practice patients. ( Cochran, KM; Penney, SC; Wood, SF, 1993) |
| " Mild adverse reactions were reported in 6 out of 23 cisapride-treated patients and in 10 out of 20 clebopride-treated patients who completed the study." | 6.67 | Clinical efficacy and safety of cisapride and clebopride in the management of chronic functional dyspepsia: a double-blind, randomized study. ( D'Angelo, V; Manzi, G; Mazzacca, G; Minieri, M; Piai, G; Sabbatini, F, 1991) |
| "Cisapride has been withdrawn last year due to the risk of potential severe cardiac arrythmies." | 6.48 | [Management of gastroparesis and functional dyspepsia after cisapride withdrawal]. ( Louis, H, 2012) |
| "We studied emptying by ultrasonography and epigastric sensations in 11 healthy subjects and in 15 patients affected by functional dyspepsia under three conditions according to a fixed schedule: (a) basal, (b) after cisapride and (c) during a 90 min hypnotic trance." | 5.12 | Prokinetic effect of gut-oriented hypnosis on gastric emptying. ( Benini, L; Chiarioni, G; De Iorio, F; Vantini, I, 2006) |
| " The aim of the study is to compare the clinical efficacy of levosulpiride and cisapride in patients with dysmotility-like functional dyspepsia." | 5.11 | Levosulpiride and cisapride in the treatment of dysmotility-like functional dyspepsia: a randomized, double-masked trial. ( Balboa, A; Jiménez, I; Mearin, F; Patón, C; Pérez-Mota, A; Rodrigo, L; Sebastián, JJ, 2004) |
| " pylori infection has an effect on the improvement of dyspeptic symptoms in response to a prokinetic agent, cisapride, in patients with non-ulcer dyspepsia (NUD)." | 5.11 | Lack of effect of Helicobacter pylori on symptom improvement with a prokinetic medication, cisapride, in patients with non-ulcer dyspepsia. ( Chaiwatanarat, T; Gonlachanvit, S; Kullavanijaya, P; Mahachai, V, 2005) |
| "To investigate whether cisapride accelerates gastric emptying in the long term or improves diabetes control in patients with diabetic gastroparesis." | 5.10 | Long-term cisapride treatment improves diabetic gastroparesis but not glycaemic control. ( Braden, B; Caspary, WF; Enghofer, M; Lembcke, B; Schaub, M; Usadel, KH, 2002) |
| "To compare the efficacy of simethicone with placebo and the prokinetic cisapride in patients with functional dyspepsia." | 5.10 | A randomized placebo-controlled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia. ( Gschossmann, J; Holtmann, G; Mayr, P; Talley, NJ, 2002) |
| "To compare the efficacy of the herbal preparation STW 5 (Iberogast ((R))) and the research preparation STW 5-II with cisapride for treatment of patients with dysmotility type of functional dyspepsia." | 5.10 | A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia. ( Rösch, W; Sassin, I; Vinson, B, 2002) |
| "To compare the efficacy of simethicone with cisapride in patients with functional (non-ulcer) dyspepsia." | 5.09 | Randomised double-blind comparison of simethicone with cisapride in functional dyspepsia. ( Becker, B; Fischer, T; Gerken, G; Gschossmann, J; Holtmann, G; Karaus, M; Mayr, P, 1999) |
| "To compare the effects of chronic oral administration of cisapride and levosulpiride in patients with functional dyspepsia and delayed gastric emptying." | 5.09 | Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis. ( Biagini, R; Borro, P; Giacomini, M; Mansi, C; Mele, MR; Pandolfo, N; Savarino, V, 2000) |
| "Cisapride provides symptomatic relief and improves gastric myoelectrical abnormalities in patients with functional dyspepsia." | 5.09 | Cisapride provides symptomatic relief in functional dyspepsia associated with gastric myoelectrical abnormality. ( Chen, JD; Ke, MY; Lin, XM; Wang, Z; Zhang, M, 2000) |
| "The aim of this study was to compare symptoms for patients with uninvestigated dyspepsia and a negative Helicobacter pylori serology who were treated with cisapride or placebo." | 5.09 | Treatment of uninvestigated dyspepsia with cisapride for patients with negative Helicobacter pylori serologies. ( Avins, AL; Kearney, DJ; McQuaid, KR, 2000) |
| " Ulcer-like dyspepsia seemed to benefit from omeprazole." | 5.09 | A randomised controlled trial of four management strategies for dyspepsia: relationships between symptom subgroups and strategy outcome. ( Buskens, E; de Wit, NJ; Lewin van den Broek, NT; Numans, ME; Smout, AJ; Verheij, TJ, 2001) |
| "To assess the efficacy of cisapride therapy in relieving symptoms of functional dyspepsia." | 5.08 | Efficacy of cisapride therapy in functional dyspepsia. ( Cowan, H; Eckstein, RP; Höschl, R; Kellow, JE; Lam, SK; Lunzer, MR; Riley, JW; Shuter, B, 1995) |
| "Cisapride and ranitidine improved the symptoms of diffuse epigastric pain, postprandial epigastric fullness, epigastric distension, belching, heartburn, regurgitation, and nausea when compared with baseline." | 5.08 | Cisapride compared with ranitidine in the treatment of functional dyspepsia. ( Carvalhinhos, A; Fidalgo, P; Freire, A; Matos, L, 1995) |
| "A controlled multi-centre clinical trial was conducted for evaluating the efficacy and safety of cisapride in the treatment of 414 cases of functional dyspepsia with 169 cases as control." | 5.08 | [A controlled multi-centre clinical trial on cisapride in treatment of functional dyspepsia]. ( Jia, B; Liang, X; Wang, B, 1995) |
| "Little is known about the prescribing habits and impact of life style or disease factors on the outcome of cisapride treatment for dyspepsia in primary care." | 5.08 | Factors affecting dose selection and outcome of cisapride treatment for dyspepsia in primary care. The Austro-Cis Study Group. ( Brunner, H, 1996) |
| "In the present double-blind placebo-controlled study the effect of cisapride on functional dyspepsia was evaluated in patients with and without histological gastritis." | 5.08 | Effect of cisapride on functional dyspepsia in patients with and without histological gastritis: a double-blind placebo-controlled trial. ( Chintana-Wilde, W; Choo, HF; Gwee, KA; Kang, JY; Tan, CC; Tay, HH; Teh, M; Wee, A; Yeoh, KG, 1997) |
| "The effects of a 2-wk course of cisapride or nizatidine in unselected patients with dyspepsia recruited from primary care were not superior to those of placebo." | 5.08 | Placebo-controlled trial of cisapride and nizatidine in unselected patients with functional dyspepsia. ( Bytzer, P; Hansen, JM; Schaffalitzky de Muckadell, OB, 1998) |
| " All patients completed a dyspepsia symptom questionnaire and were then treated with cisapride 10 mg t." | 5.08 | The effect of cisapride on dyspepsia symptoms and the electrogastrogram in patients with non-ulcer dyspepsia. ( Besherdas, K; Epstein, O; Harbord, M; Leahy, A; Mason, I, 1998) |
| "To test the effect of cisapride on symptom score and on fasting and postprandial antral area in patients with dysmotility-like functional dyspepsia compared with controls." | 5.08 | The effect of cisapride on dysmotility-like functional dyspepsia: reduction of the fasting and postprandial area, but not of the postprandial antral expansion. ( Barnert, J; Dumitrascu, DL; Eberl, T; Fischer, J; Wienbeck, M, 1998) |
| "The efficacy and tolerability of cisapride (5 mg three times daily) and metoclopramide (10 mg three times daily) were evaluated in a randomized double-blind trial in patients with functional dyspepsia." | 5.07 | Cisapride versus metoclopramide in the treatment of functional dyspepsia. A double-blind comparative trial. ( Fumagalli, I; Hammer, B, 1994) |
| "The efficacy and tolerability of Cisapride effervescent granules and a metoclopramide-dimethicone combination were compared double-blind in two comparable groups of 15 patients each with dyspepsia." | 5.07 | [Efficacy and tolerability of cisapride in a new formula of 10 mg effervescent capsules for the treatment of functional dyspepsia]. ( Di Felice, F; Grossi, L; Marzio, L, 1993) |
| "Twenty patients with functional dyspepsia were referred for radiologic examination and, upon confirmation of a hypomotile stomach, were given either 10 mg cisapride or placebo in a double-blind manner (10 patients per group)." | 5.07 | A double-blind fluoroscopic study of cisapride on gastrointestinal motility in patients with functional dyspepsia. ( De Schepper, A; Degryse, H; Verlinden, M, 1993) |
| "The efficacy and tolerability of cisapride in chronic dyspepsia was evaluated in a randomized, double-blind, placebo-controlled study." | 5.07 | Cisapride in chronic dyspepsia: results of a double-blind, placebo-controlled trial. ( Chung, JM, 1993) |
| "In a Dutch general practice trial conducted in 599 patients with symptoms of dyspepsia, the response to 5 mg cisapride three times daily was rated excellent or good in 61% of patients at week 2." | 5.07 | Factors affecting short- and long-term outcome of a short therapeutic trial with cisapride in dyspeptic patients. ( Hazelhoff, B; Heyse, PM; Rambaldo, R, 1993) |
| "A double-blind, placebo-controlled trial was performed to determine the therapeutic efficacy of cisapride in patients with refractory functional dyspepsia." | 5.07 | Efficacy of cisapride in functional dyspepsia resistant to domperidone or metoclopramide: a double-blind, placebo-controlled study. ( De Nutte, N; Gooris, JP; Van Eeghem, P; Van Outryve, M, 1993) |
| "One hundred and twenty consecutive outpatients with non-ulcer dyspepsia (NUD) and erosive prepyloric changes (EPC) were, after a 2-week placebo run-in period, randomly allocated to double-blind treatment with either 10-mg cisapride tablets or placebo three times daily for 4 weeks." | 5.07 | Cisapride treatment of patients with non-ulcer dyspepsia and erosive prepyloric changes. A double-blind, placebo-controlled trial. ( Berstad, A; Hausken, T, 1992) |
| "Fasting antral area was examined by ultrasonography in 40 healthy subjects and in 106 patients with non-ulcer dyspepsia (NUD) and erosive prepyloric changes (EPC) before and after treatment with cisapride or placebo." | 5.07 | Wide gastric antrum in patients with non-ulcer dyspepsia. Effect of cisapride. ( Berstad, A; Hausken, T, 1992) |
| "The effects on gastric emptying and gastrointestinal symptoms of treatment with cisapride alone and in combination with domperidone were investigated in 25 patients with chronic idiopathic dyspepsia." | 5.07 | Effect of treatment with cisapride alone or in combination with domperidone on gastric emptying and gastrointestinal symptoms in dyspeptic patients. ( Iishi, H; Nakaizumi, A; Okuda, S; Tatsuta, M, 1992) |
| "Controlled studies showed that cisapride is effective in non-ulcer dyspepsia." | 5.07 | [Cisapride: clinical experience in 1071 patients with non-ulcer dyspepsia or reflux symptoms]. ( Fehr, HF, 1991) |
| "In a randomized, double-blind, placebo-controlled study, 32 patients with nonulcer dyspepsia received 5 mg of cisapride or placebo three times daily for four weeks after a two-week run-in phase on placebo." | 5.06 | Relief of epigastric pain in nonulcer dyspepsia: controlled trial of the promotility drug cisapride. ( De Nutte, N; Defrance, P; Van Ganse, W; Witterhulghe, M, 1989) |
| " It was the aim of this study to assess the acute effects of cisapride on antroduodenal motility and duodenogastric reflux in seven patients with severe dyspepsia and increased biliary reflux, as evidenced by increased bile salt output in their gastric aspirates." | 5.06 | Cisapride stimulates antral motility and decreases biliary reflux in patients with severe dyspepsia. ( Di Lorenzo, C; Dooley, CP; Rezende-Filho, J; Valenzuela, JE, 1989) |
| "The effects of cisapride, a nondopaminolytic motility-enhancing agent, were studied in 56 patients with chronic functional dyspepsia; all had symptoms suggestive of delayed gastric emptying." | 5.06 | Cisapride in the management of chronic functional dyspepsia: a multicenter, double-blind, placebo-controlled study. ( Deruyttere, M; Heylen, H; Lepoutre, L; Pennoit, H; Samain, H, 1987) |
| "In a double blind crossover comparison with placebo, the effects of cisapride (10 mg tid for two weeks), a non-antidopaminergic gastrointestinal prokinetic drug, on gastric emptying times and on symptoms were evaluated in 12 patients with chronic idiopathic dyspepsia and gastroparesis." | 5.06 | Effect of chronic administration of cisapride on gastric emptying of a solid meal and on dyspeptic symptoms in patients with idiopathic gastroparesis. ( Barbara, L; Corinaldesi, R; Raiti, C; Rea, E; Salgemini, R; Stanghellini, V, 1987) |
| "The effect of cisapride, 10 mg three times daily, was evaluated in a double-blind randomized study in 118 patients with non-ulcer dyspepsia." | 5.06 | Cisapride in non-ulcer dyspepsia. Results of a placebo-controlled trial. ( Rösch, W, 1987) |
| " A dual isotopic technique was used to evaluate patients with non-obstructive dyspepsia (idiopathic and secondary) (part 1) and to assess the effects of a new gastrokinetic agent: cisapride, on gastric emptying in such patients (part 2)." | 5.05 | Measurement of gastric emptying in dyspeptic patients: effect of a new gastrokinetic agent (cisapride). ( Bernier, JJ; Ducrot, F; Jian, R; Mary, JY; Najean, Y; Piedeloup, C, 1985) |
| "Evidence for the effectiveness of antacids, histamine-2 receptor antagonists, bismuth salts, sucralfate and prokinetic therapy in non-ulcer dyspepsia is conflicting." | 4.82 | Systematic review: Antacids, H2-receptor antagonists, prokinetics, bismuth and sucralfate therapy for non-ulcer dyspepsia. ( Deeks, J; Delaney, B; Forman, D; Harris, A; Innes, M; Moayyedi, P; Soo, S, 2003) |
| "Both cisapride and domperidone seem to be efficacious in functional dyspepsia, although this conclusion is largely based on global assessment by the investigator, which may not be an optimal outcome measure." | 4.81 | Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. ( Jones, MJ; Talley, NJ; Veldhuyzen van Zanten, SJ; Verlinden, M, 2001) |
| "Based on these data both treatments are significantly more effective than placebo in the symptomatic treatment of non-ulcer dyspepsia, with gastroprokinetics (cisapride, domperidone) being more effective than histamine H2-receptor antagonists (cimetidine, ranitidine)." | 4.81 | Treatment of non-ulcer dyspepsia: a meta-analysis of placebo-controlled prospective studies. ( Allescher, HD; Böckenhoff, A; Hartung, J; Knapp, G; Wienbeck, M, 2001) |
| "This paper provides a comprehensive review of the current knowledge on cisapride in different clinical conditions in children: different manifestations of gastro-oesophageal reflux, such as (excessive) regurgitation, oesophagitis, chronic respiratory disease or uncontrolled asthma, cystic fibrosis, chronic dyspepsia, constipation and pseudo-obstruction, and as an aid to small bowel capsule-biopsy." | 4.80 | Clinical use of cisapride and its risk-benefit in paediatric patients. ( Vandenplas, Y, 1998) |
| "The withdrawal of cisapride from the market will present challenges for physicians treating patients with nocturnal heartburn, gastroparesis, and dyspepsia." | 4.80 | Cisapride: limited access and alternatives. ( Richter, JE, 2000) |
| "For the drug treatment of gastroparesis, domperidone, metoclopramide and cisapride may be prescribed as prokinetics." | 4.80 | [Treatment of severely delayed gastric emptying]. ( Gooszen, HG; Samsom, M, 2000) |
| " These pharmacological differences have clinical relevance: metoclopramide and domperidon could not consistently prove efficacy in functional dyspepsia and GORD." | 4.79 | [Pharmacologic and clinical differentiation of prokinetic drugs]. ( Greving, I; May, B, 1996) |
| "The authors describe the gastro-kinetic drugs that act on functional dyspepsia including metoclopramide, domperidone, clebopride cisapride." | 4.78 | [Therapy of non-ulcer dyspepsia]. ( Cortese, I; Maselli, MA, 1990) |
| "Non-ulcer dyspepsia is gaining increasing interest among gastroenterologists even though the pathogenetic mechanisms in individual patients are still unknown." | 3.76 | Efficacy of cisapride in the treatment of epigastric pain and concomitant symptoms in non-ulcer dyspepsia. ( Rösch, W, 1989) |
| " Continuous 24-h ECG recording detected a ventricular tachycardia in torsades de pointes inducing a syncopal convulsive attack that seemed to be related to oral Cisapride assumption for dyspepsia." | 3.74 | An anorexic woman with convulsive loss of consciousness. Syncope or epileptic fits? ( Argiriadou, V; Attanasio, A; Diomedi, M; Sandri, G, 2007) |
| "20 out of 35 patients received 10 mg cisapride three times-daily for two weeks, that resulted in amelioration of dyspepsia symptoms and a parallel improvement in EGG parameters in 18 patients." | 3.73 | [Electrogastrography monitoring of the effectiveness of prokinetic and cognitive therapy in functional dyspepsia]. ( Fodor, G; Gyökeres, T; Pap, A; Schwab, R, 2005) |
| "Drug-induced symptoms of functional dyspepsia are rare and do not contribute to the use of cisapride." | 3.70 | Drug-induced symptoms of functional dyspepsia and nausea. A symmetry analysis of one million prescriptions. ( Bytzer, P; Hallas, J, 2000) |
| "[13C]Acetate and [13C]octanoate breath tests were used to analyze the gastric emptying of liquids and solids in healthy controls and patients with functional dyspepsia both with and without cisapride." | 3.69 | Influence of cisapride on gastric emptying of solids and liquids monitored by 13C breath tests. ( Braden, B; Caspary, WF; Duan, LP; Lembcke, B, 1995) |
| "We examined the effect of oral cisapride on gastric emptying time and myoelectrical activity using real-time ultrasonography and cutaneous electrogastrography in 10 children with nonulcer dyspepsia." | 3.69 | Gastric emptying and myoelectrical activity in children with nonulcer dyspepsia. Effect of cisapride. ( Chiloiro, M; Cucchiara, S; Giorgio, I; Guerra, V; Minella, R; Riezzo, G, 1995) |
| " This study investigated the correlation between clinical improvement and quality of life after 12 months of treatment with cisapride or domperidone in patients with severe dyspepsia." | 3.69 | Symptom improvement from prokinetic therapy corresponds to improved quality of life in patients with severe dyspepsia. ( Abell, TL; Cutts, TF; Karas, JG; Kuns, J, 1996) |
| "Gastric emptying in 14 patients with chronic hepatitis C was estimated by the sulfamethizole capsule method before and 1 and 2 weeks after the beginning of interferon-alpha (6 million U/day) therapy." | 3.69 | Delayed gastric emptying during interferon-alpha therapy in patients with chronic hepatitis C: relief by cisapride. ( Kanayama, S; Kawata, S; Matsuzawa, Y; Nishibayashi, H; Shinomura, Y, 1997) |
| "In a 28-day non-blinded study of 1071 patients with functional dyspeptic symptoms in a general practice setting, 666 presented with mainly typical symptoms of functional dyspepsia and received 5 mg cisapride three times daily, while 405 with predominating symptoms indicative of gastroesophageal reflux received 10 mg cisapride three times daily." | 3.68 | Risk factors, co-medication, and concomitant diseases: their influence on the outcome of therapy with cisapride. ( Fehr, HF, 1993) |
| "An open prospective drug monitoring study was undertaken to assess the efficacy and tolerability of 5 mg cisapride three times daily in 37,925 general practice patients with functional dyspepsia." | 3.68 | A German drug-monitoring study in general practice patients receiving cisapride for functional dyspepsia. ( Liehr, H; Schmidt, R, 1993) |
| "Cisapride was significantly more effective than lansoprazole (OR 0." | 2.82 | Comparative Efficacy of Various Pharmacological Interventions in the Treatment of Functional Dyspepsia: A Network Meta-Analysis. ( Liang, L; Wang, G; Xiao, L; Yu, J, 2022) |
| "Treatment with omeprazole provides superior symptom relief compared to ranitidine, cisapride, and placebo in the treatment of H." | 2.71 | A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study. ( Armstrong, D; Barkun, A; Chiba, N; Escobedo, S; Lee, J; Sinclair, P; Smyth, S; Thomson, A; Veldhuyzen van Zanten, SJ, 2005) |
| "Treatment with cisapride increased sympathetic tone in the patient group but had no effect on vagal tone." | 2.69 | Effect of mental stress and cisapride on autonomic nerve functions in functional dyspepsia. ( Berstad, A; Hausken, T; Hveem, K; Svebak, S, 1998) |
| "Pre-treatment with cisapride significantly lowered thresholds for perception and for discomfort, both during isobaric (4." | 2.69 | The influence of cisapride on gastric tone and the perception of gastric distension. ( Broeckaert, D; Coulie, B; Janssens, J; Tack, J, 1998) |
| "Cisapride is an effective and well-tolerated treatment for FD in Saudi Arabs." | 2.68 | A double-blind, randomized, placebo-controlled trial of cisapride in Saudi Arabs with functional dyspepsia. ( al-Quorain, A; al-Shedoki, F; Larbi, EB, 1995) |
| "Functional dyspepsia is recognized as a common disorder in clinical practice." | 2.68 | Cisapride in functional dyspepsia in general practice. A placebo-controlled, randomized, double-blind study. ( de Both, PS; de Groot, GH, 1997) |
| "Cisapride is a substituted benzamide with gastrointestinal prokinetic effects presumed to be due to the enhancement of the physiological release of acetylcholine at the myenteric plexus." | 2.68 | A double-blind randomized study of cisapride in the treatment of nonulcer dyspepsia. The Canadian Cisapride Nud Study Group. ( Archambault, A; Champion, MC; Eberhard, S; MacCannell, KL; Sullivan, SN; Tanton, R; Thomson, AB, 1997) |
| "Cisapride was more effective than domperidone in the REFLUX-Group." | 2.68 | Study with two prokinetics in functional dyspepsia and GORD: domperidone vs. cisapride. ( Guyot, J; Halter, F; Hammer, B; Miazza, BM; Staub, P, 1997) |
| "Functional dyspepsia is a major diagnostic and therapeutic challenge for the clinician." | 2.67 | Cisapride or cimetidine in the treatment of functional dyspepsia. Results of a double-blind, randomized, Swiss multicentre study. ( Brignoli, R; Halter, F; Miazza, B, 1994) |
| "We conducted a double-blind study comparing two dosage regimens of a prokinetic drug, cisapride (10 mg q." | 2.67 | Two different dose regimens of cisapride in the treatment of reflux oesophagitis: a double-blind comparison with ranitidine. ( Geldof, H; Hazelhoff, B; Otten, MH, 1993) |
| "Cisapride was well tolerated." | 2.67 | Cisapride in functional dyspepsia: a double-blind, placebo-controlled randomized trial in general practice patients. ( Cochran, KM; Penney, SC; Wood, SF, 1993) |
| "Cisapride treatment reversed the gallbladder hypomotility within the normal range while placebo did not change the response to meal." | 2.67 | Gallbladder hypokinesia and normal gastric emptying of liquids in patients with dyspeptic symptoms. A double-blind placebo-controlled clinical trial with cisapride. ( Cuccurullo, F; DiFelice, F; Imbimbo, B; Laico, MG; Lapenna, D; Marzio, L, 1992) |
| " Mild adverse reactions were reported in 6 out of 23 cisapride-treated patients and in 10 out of 20 clebopride-treated patients who completed the study." | 2.67 | Clinical efficacy and safety of cisapride and clebopride in the management of chronic functional dyspepsia: a double-blind, randomized study. ( D'Angelo, V; Manzi, G; Mazzacca, G; Minieri, M; Piai, G; Sabbatini, F, 1991) |
| "Dyspepsia is a common condition associated with gastrointestinal (GI) disease." | 2.58 | Prokinetics for functional dyspepsia. ( Bollegala, NP; Khanna, R; Leontiadis, GI; Moayyedi, P; Pittayanon, R; Yuan, Y, 2018) |
| "Cisapride has been withdrawn last year due to the risk of potential severe cardiac arrythmies." | 2.48 | [Management of gastroparesis and functional dyspepsia after cisapride withdrawal]. ( Louis, H, 2012) |
| "Non-ulcer dyspepsia is common and is often confused with other diagnoses." | 2.42 | Update on the role of drug therapy in non-ulcer dyspepsia. ( Talley, NJ, 2003) |
| "Functional dyspepsia is a heterogeneous clinical entity of incompletely known etiology." | 2.42 | [The efficacy of a combination herbal medicine in the treatment of functional dyspepsia. Meta-analysis of randomized double-blind studies on the basis of a valid gastrointestinal symptom profile]. ( Godehardt, E; Gundermann, KJ; Ulbrich, M, 2004) |
| "Dyspepsia is most optimally defined as pain or discomfort centred in the upper abdomen." | 2.40 | Management guidelines for uninvestigated and functional dyspepsia in the Asia-Pacific region: First Asian Pacific Working Party on Functional Dyspepsia. ( Fock, KM; Goh, KL; Lam, SK; Talley, NJ, 1998) |
| "Functional gastrointestinal disorders are best understood by applying a bio-psycho-social model." | 2.40 | Today's therapy of functional gastrointestinal disorders--does it help? ( Berstad, A, 1998) |
| "Cisapride was either equal to or superior to metoclopramide in relieving reflux symptoms." | 2.39 | Cisapride: a gastrointestinal prokinetic drug. ( Barone, JA; Bierman, RH; Colaizzi, JL; Jessen, LM, 1994) |
| "Dyspepsia affects one in four Australians; of those who present in general practice, the majority will have functional or non-ulcer dyspepsia, with no structural explanation for their symptoms." | 2.39 | Modern management of dyspepsia. ( Talley, NJ, 1996) |
| "Functional dyspepsia is one of the most common functional disorders of the gastrointestinal tract, which resulted from impaired motor skills, visceral hypersensitivity, increased mucosal permeability, disorders of the autonomic nervous system, etc." | 1.62 | [Rational treatment of patients with functional dyspepsia]. ( Kazakov, AS; Nasretdinova, EK; Ushkalova, EA; Zyryanov, SK, 2021) |
| "Chronic dyspepsia is common in children." | 1.31 | Nutritional implications of chronic dyspepsia in childhood. ( Bartsocas, C; Papadimitriou, A; Papadopoulou, A; Siafakas, C; Vazeou, A, 2002) |
| "Cisapride was well tolerated and thus appears to be a useful option in the treatment of functional digestive disorders in a general practice setting." | 1.29 | Functional dyspepsia versus other functional gastrointestinal disorders: a practical approach in Belgian general practices. ( Cardon, E; Jaecques, N; Lebrun, F; Meurant, JP; Rombouts, J; Spaepen, W; Verhaeghe, J, 1993) |
| "Cisapride appears to be a good alternative to metoclopramide and domperiodone in the treatment of dyspeptic patients." | 1.27 | Effect of cisapride on gastric emptying in dyspeptic patients. ( Debie, NC; Pauwels, SP; Siegel, JA; Urbain, JL, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (10.79) | 18.7374 |
| 1990's | 78 (56.12) | 18.2507 |
| 2000's | 38 (27.34) | 29.6817 |
| 2010's | 5 (3.60) | 24.3611 |
| 2020's | 3 (2.16) | 2.80 |
| Authors | Studies |
|---|---|
| Kazakov, AS | 1 |
| Zyryanov, SK | 1 |
| Ushkalova, EA | 1 |
| Nasretdinova, EK | 1 |
| Goelen, N | 1 |
| Jones, M | 1 |
| Huang, IH | 1 |
| Carbone, F | 1 |
| Janssen, P | 1 |
| Tack, J | 3 |
| Liang, L | 1 |
| Yu, J | 1 |
| Xiao, L | 1 |
| Wang, G | 1 |
| Pittayanon, R | 1 |
| Yuan, Y | 1 |
| Bollegala, NP | 1 |
| Khanna, R | 1 |
| Leontiadis, GI | 1 |
| Moayyedi, P | 2 |
| Vijayvargiya, P | 1 |
| Camilleri, M | 1 |
| Chedid, V | 1 |
| Mandawat, A | 1 |
| Erwin, PJ | 1 |
| Murad, MH | 1 |
| Lan, L | 1 |
| Zeng, F | 1 |
| Liu, GJ | 1 |
| Ying, L | 1 |
| Wu, X | 1 |
| Liu, M | 1 |
| Liang, FR | 1 |
| Mearín, F | 2 |
| Plazas, MJ | 1 |
| Mas, M | 1 |
| Heras, J | 1 |
| Louis, H | 1 |
| Rösch, W | 7 |
| Vinson, B | 3 |
| Sassin, I | 2 |
| Braden, B | 2 |
| Enghofer, M | 1 |
| Schaub, M | 1 |
| Usadel, KH | 1 |
| Caspary, WF | 2 |
| Lembcke, B | 2 |
| Holtmann, G | 4 |
| Gschossmann, J | 2 |
| Mayr, P | 2 |
| Talley, NJ | 6 |
| Soo, S | 1 |
| Deeks, J | 1 |
| Forman, D | 1 |
| Harris, A | 1 |
| Innes, M | 1 |
| Delaney, B | 1 |
| Caenepeel, P | 1 |
| Piessevaux, H | 1 |
| Cuomo, R | 1 |
| Janssens, J | 2 |
| Rodrigo, L | 1 |
| Pérez-Mota, A | 1 |
| Balboa, A | 1 |
| Jiménez, I | 1 |
| Sebastián, JJ | 1 |
| Patón, C | 1 |
| Buzás, GM | 1 |
| Veldhuyzen van Zanten, SJ | 3 |
| Chiba, N | 2 |
| Armstrong, D | 2 |
| Barkun, A | 2 |
| Thomson, A | 2 |
| Smyth, S | 1 |
| Escobedo, S | 1 |
| Lee, J | 1 |
| Sinclair, P | 2 |
| Fodor, G | 1 |
| Schwab, R | 1 |
| Gyökeres, T | 1 |
| Pap, A | 1 |
| Gonlachanvit, S | 1 |
| Mahachai, V | 1 |
| Chaiwatanarat, T | 1 |
| Kullavanijaya, P | 1 |
| Chiarioni, G | 1 |
| Vantini, I | 1 |
| De Iorio, F | 1 |
| Benini, L | 1 |
| Gundermann, KJ | 2 |
| Godehardt, E | 1 |
| Ulbrich, M | 1 |
| Ang, TL | 1 |
| Fock, KM | 2 |
| Teo, EK | 1 |
| Chan, YH | 1 |
| Ng, TM | 1 |
| Chua, TS | 1 |
| Tan, JY | 1 |
| Liebregts, T | 1 |
| Attanasio, A | 1 |
| Argiriadou, V | 1 |
| Sandri, G | 1 |
| Diomedi, M | 1 |
| Hiyama, T | 2 |
| Yoshihara, M | 2 |
| Matsuo, K | 2 |
| Kusunoki, H | 2 |
| Kamada, T | 2 |
| Ito, M | 2 |
| Tanaka, S | 2 |
| Nishi, N | 1 |
| Chayama, K | 2 |
| Haruma, K | 2 |
| Sheptulin, AA | 1 |
| al-Quorain, A | 1 |
| Larbi, EB | 1 |
| al-Shedoki, F | 1 |
| Duan, LP | 1 |
| Kellow, JE | 2 |
| Cowan, H | 1 |
| Shuter, B | 1 |
| Riley, JW | 1 |
| Lunzer, MR | 1 |
| Eckstein, RP | 1 |
| Höschl, R | 1 |
| Lam, SK | 2 |
| Carvalhinhos, A | 1 |
| Fidalgo, P | 1 |
| Freire, A | 1 |
| Matos, L | 1 |
| Riezzo, G | 2 |
| Cucchiara, S | 3 |
| Chiloiro, M | 1 |
| Minella, R | 3 |
| Guerra, V | 1 |
| Giorgio, I | 1 |
| Jia, B | 2 |
| Wang, B | 1 |
| Liang, X | 1 |
| Halter, F | 3 |
| Miazza, B | 1 |
| Brignoli, R | 2 |
| Barone, JA | 1 |
| Jessen, LM | 1 |
| Colaizzi, JL | 1 |
| Bierman, RH | 1 |
| Fumagalli, I | 1 |
| Hammer, B | 2 |
| Geldof, H | 1 |
| Hazelhoff, B | 2 |
| Otten, MH | 1 |
| Lee, S | 1 |
| Grossi, L | 1 |
| Di Felice, F | 1 |
| Marzio, L | 2 |
| Frazzoni, M | 1 |
| Lonardo, A | 1 |
| Grisendi, A | 1 |
| Della Casa, G | 1 |
| Pulvirenti, M | 1 |
| Ferrari, AM | 1 |
| Di Gregorio, C | 1 |
| Melini, L | 1 |
| Degryse, H | 1 |
| De Schepper, A | 1 |
| Verlinden, M | 3 |
| Chung, JM | 1 |
| Heyse, PM | 1 |
| Rambaldo, R | 1 |
| Verhaeghe, J | 1 |
| Jaecques, N | 1 |
| Rombouts, J | 1 |
| Spaepen, W | 1 |
| Cardon, E | 1 |
| Lebrun, F | 1 |
| Meurant, JP | 1 |
| Fehr, HF | 2 |
| Inoue, M | 1 |
| Sekiguchi, T | 2 |
| Harasawa, S | 2 |
| Miwa, T | 1 |
| Miyoshi, A | 1 |
| Van Outryve, M | 1 |
| De Nutte, N | 2 |
| Van Eeghem, P | 1 |
| Gooris, JP | 1 |
| Wood, SF | 1 |
| Penney, SC | 1 |
| Cochran, KM | 1 |
| Liehr, H | 1 |
| Schmidt, R | 1 |
| Abell, TL | 2 |
| Cutts, TF | 2 |
| Cooper, T | 1 |
| Raia, V | 1 |
| Frezza, T | 1 |
| De Vizia, B | 1 |
| De Ritis, G | 1 |
| Karas, JG | 1 |
| Kuns, J | 1 |
| Hveem, K | 2 |
| Hausken, T | 4 |
| Svebak, S | 2 |
| Berstad, A | 5 |
| Brunner, H | 1 |
| May, B | 1 |
| Greving, I | 1 |
| Haycox, A | 1 |
| de Groot, GH | 1 |
| de Both, PS | 1 |
| Yeoh, KG | 1 |
| Kang, JY | 1 |
| Tay, HH | 1 |
| Gwee, KA | 1 |
| Tan, CC | 1 |
| Wee, A | 1 |
| Teh, M | 1 |
| Choo, HF | 1 |
| Chintana-Wilde, W | 1 |
| Champion, MC | 2 |
| MacCannell, KL | 1 |
| Thomson, AB | 1 |
| Tanton, R | 1 |
| Eberhard, S | 1 |
| Sullivan, SN | 1 |
| Archambault, A | 1 |
| Prassler, R | 1 |
| Huchzermeyer, H | 1 |
| Watkins, P | 1 |
| Nishibayashi, H | 1 |
| Kanayama, S | 1 |
| Shinomura, Y | 1 |
| Kawata, S | 1 |
| Matsuzawa, Y | 1 |
| Staub, P | 1 |
| Guyot, J | 1 |
| Miazza, BM | 1 |
| Hansen, JM | 2 |
| Bytzer, P | 5 |
| Schaffalitzky de Muckadell, OB | 1 |
| Adelman, A | 1 |
| Alper, BS | 1 |
| Goh, KL | 1 |
| Besherdas, K | 1 |
| Leahy, A | 1 |
| Mason, I | 1 |
| Harbord, M | 1 |
| Epstein, O | 1 |
| Broeckaert, D | 1 |
| Coulie, B | 1 |
| Vandenplas, Y | 1 |
| Eberl, T | 1 |
| Barnert, J | 1 |
| Dumitrascu, DL | 1 |
| Fischer, J | 1 |
| Wienbeck, M | 2 |
| Chen, R | 1 |
| Kang, M | 1 |
| Karaus, M | 1 |
| Fischer, T | 1 |
| Becker, B | 1 |
| Gerken, G | 1 |
| Madisch, A | 1 |
| Heydenreich, CJ | 1 |
| Wieland, V | 1 |
| Hufnagel, R | 1 |
| Hotz, J | 1 |
| Mansi, C | 1 |
| Borro, P | 1 |
| Giacomini, M | 1 |
| Biagini, R | 1 |
| Mele, MR | 1 |
| Pandolfo, N | 1 |
| Savarino, V | 1 |
| Richter, JE | 1 |
| Chen, JD | 1 |
| Ke, MY | 1 |
| Lin, XM | 1 |
| Wang, Z | 1 |
| Zhang, M | 1 |
| Kearney, DJ | 1 |
| Avins, AL | 1 |
| McQuaid, KR | 1 |
| Flook, N | 1 |
| Bradette, M | 1 |
| Bursey, F | 1 |
| Blackshaw, P | 1 |
| Frail, D | 1 |
| Samsom, M | 1 |
| Gooszen, HG | 1 |
| Hallas, J | 1 |
| Jones, MJ | 1 |
| Radwan, P | 1 |
| Grodzieński, R | 1 |
| Zaorska-Rajca, J | 1 |
| Skrzydło-Radomańska, B | 1 |
| Słomka, M | 1 |
| Wysokiński, A | 1 |
| Lewin van den Broek, NT | 1 |
| Numans, ME | 2 |
| Buskens, E | 1 |
| Verheij, TJ | 1 |
| de Wit, NJ | 2 |
| Smout, AJ | 1 |
| Allescher, HD | 1 |
| Böckenhoff, A | 1 |
| Knapp, G | 2 |
| Hartung, J | 2 |
| Quartero, AO | 1 |
| de Melker, RA | 1 |
| Hoes, AW | 1 |
| Spiroglou, K | 1 |
| Chatziparasidis, G | 1 |
| Paroutoglou, G | 1 |
| Demertzidou, V | 1 |
| Giouleme, O | 1 |
| Nikolaides, N | 1 |
| Evgenides, N | 1 |
| Papadopoulou, A | 1 |
| Vazeou, A | 1 |
| Siafakas, C | 1 |
| Papadimitriou, A | 1 |
| Bartsocas, C | 1 |
| Hongo, M | 1 |
| Satake, M | 1 |
| Møller, J | 1 |
| Schaffalitzky de Muckadell, O | 1 |
| Jian, R | 3 |
| Tatsuta, M | 1 |
| Iishi, H | 1 |
| Nakaizumi, A | 1 |
| Okuda, S | 1 |
| Vallone, G | 1 |
| Vallone, P | 1 |
| Castellone, F | 1 |
| Auricchio, S | 1 |
| DiFelice, F | 1 |
| Laico, MG | 1 |
| Imbimbo, B | 1 |
| Lapenna, D | 1 |
| Cuccurullo, F | 1 |
| Sabbatini, F | 1 |
| Minieri, M | 1 |
| Manzi, G | 1 |
| Piai, G | 1 |
| D'Angelo, V | 1 |
| Mazzacca, G | 1 |
| Horikoshi, T | 1 |
| Nishioka, T | 1 |
| Kusano, M | 1 |
| Matsuzaki, T | 1 |
| Kawamura, O | 1 |
| Miyazaki, M | 1 |
| Kikuchi, K | 1 |
| Iwanaga, Y | 1 |
| Miyashita, N | 1 |
| Mizutani, F | 1 |
| Morikawa, K | 1 |
| Kato, H | 1 |
| Ito, Y | 1 |
| Itoh, Z | 1 |
| Canepa, G | 1 |
| Di Somma, C | 1 |
| Arnulfo, G | 1 |
| Frascio, M | 1 |
| Berti Riboli, E | 1 |
| Cortese, I | 1 |
| Maselli, MA | 1 |
| Lux, G | 1 |
| Lederer, P | 1 |
| Takayasu, H | 1 |
| Testoni, PA | 1 |
| Bagnolo, F | 1 |
| Fanti, L | 1 |
| Passaretti, S | 1 |
| Tittobello, A | 1 |
| Demling, L | 2 |
| Brogna, A | 1 |
| Ferrara, R | 1 |
| Scornavacca, G | 1 |
| Lombardo, A | 1 |
| Bucceri, A | 1 |
| Catalano, F | 1 |
| Paradisi, V | 1 |
| Onorato, S | 1 |
| Ducrot, F | 2 |
| Ruskone, A | 1 |
| Chaussade, S | 1 |
| Rambaud, JC | 1 |
| Modigliani, R | 1 |
| Rain, JD | 1 |
| Bernier, JJ | 2 |
| Van Ganse, W | 1 |
| Witterhulghe, M | 1 |
| Defrance, P | 1 |
| Fraitag, B | 1 |
| Cloarec, D | 1 |
| Galmiche, JP | 1 |
| Johnson, AG | 1 |
| Graham, JR | 1 |
| Rezende-Filho, J | 1 |
| Di Lorenzo, C | 1 |
| Dooley, CP | 1 |
| Valenzuela, JE | 1 |
| Deruyttere, M | 1 |
| Lepoutre, L | 1 |
| Heylen, H | 1 |
| Samain, H | 1 |
| Pennoit, H | 1 |
| Urbain, JL | 1 |
| Siegel, JA | 1 |
| Debie, NC | 1 |
| Pauwels, SP | 1 |
| Ceccanti, M | 1 |
| De Lorenzo, A | 1 |
| Romeo, M | 1 |
| Panijel, M | 1 |
| Schwarz, W | 1 |
| Dilla, H | 1 |
| Giesecke, HJ | 1 |
| Gabriel, H | 1 |
| Kullik, R | 1 |
| Leber, W | 1 |
| Weitendorff, F | 1 |
| Daake, H | 1 |
| Corinaldesi, R | 1 |
| Stanghellini, V | 1 |
| Raiti, C | 1 |
| Rea, E | 1 |
| Salgemini, R | 1 |
| Barbara, L | 1 |
| Piedeloup, C | 1 |
| Mary, JY | 1 |
| Najean, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Self-Administered Hypnotherapy for Functional Dyspepsia[NCT03884270] | 23 participants (Actual) | Interventional | 2019-05-03 | Completed | |||
| Peppermint Oil as an Alternative Treatment for Children With Bladder and Bowel Dysfunction: A Prospective Study[NCT05613153] | 30 participants (Anticipated) | Interventional | 2022-11-01 | Enrolling by invitation | |||
| Randomized Controlled Pilot Trial of Cereset Research For Chronic Nausea[NCT05229107] | 24 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Feasibility will be calculated as the proportion of participants who complete the hypnotherapy treatment program in comparison to those who drop out before treatment is completed. (NCT03884270)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Hypnotherapy | 22 |
The BSI is an 18-item self-report questionnaire with responses on a 5-point Likert scale, ranging from 0 (not bothered by a symptom at all) to 4 (extremely bothered). Three subscales are calculated (somatization, depression, and anxiety) and the subscales can be aggregated to calculate an overall global psychological distress score. The overall score and subscale scores are converted to T-scores (with a population mean of 50 and a standard deviation of 10). Higher T-scores indicate more psychological distress and T-scores ≥63 indicate clinically significant psychological distress. The BSI score was regressed on the fixed effect of time period in a linear mixed effects regression model that included random intercepts to account for within-participant correlation. Least square mean differences were calculated as 3-month follow-up minus baseline. (NCT03884270)
Timeframe: Baseline, 3 months
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Hypnotherapy | -9.22 |
The PAGI-SYM is a 20-item self-report measure of functional dyspepsia symptom severity. The scale consists of 6 subscales (heartburn/regurgitation, nausea/vomiting, postprandial fullness/early satiety, bloating, upper abdominal pain, and lower abdominal pain). Each item is measured by a 6-point Likert scale ranging from 0 (no complaints) to 5 (severe complaints). Subscale scores are calculated by taking the mean of the items in each subscale. The total score is calculated by taking the mean of the subscale scores. Total scores range from 0 to 5, with higher scores indicating worse symptoms. The PAGI-SYM total score was regressed on the fixed effect of time period in a linear mixed effects regression model that included random intercepts to account for within-participant correlation. Least square mean differences were calculated as 3-month follow-up minus baseline. (NCT03884270)
Timeframe: Baseline, 3-months
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Hypnotherapy | -0.82 |
The NDI-SF is a 10-item self-report disease specific quality of life questionnaire. The scale consists of 5 sub-scales (tension/anxiety, interference with daily activities, disruption to regular eating/drinking, knowledge towards/control over disease, interference with work/study). Each item is measured by a 5-point Likert scale ranging from 0 (not applicable) to 4 (extremely). Individual items are aggregated to obtain a total score ranging from 0 to 100 with higher scores indicating greater impairment in quality of life. The NDI-SF score was regressed on the fixed effect of time period in a linear mixed effects regression model that included random intercepts to account for within-participant correlation. Least square mean differences were calculated as 3-month follow-up minus baseline. (NCT03884270)
Timeframe: Baseline, 3 months
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Hypnotherapy | -9.65 |
The VSI is a 15-item self-report questionnaire with responses ranging from 1 (strongly agree) to 6 (strongly disagree). The raw VSI score ranges from 0 (severe anxiety) to 75 (no anxiety). The VSI score was regressed on the fixed effect of time period in a linear mixed effects regression model that included random intercepts to account for within-participant correlation. Least square mean differences were calculated as 3-month follow-up minus baseline. (NCT03884270)
Timeframe: Baseline, 3 months
| Intervention | score on a scale (Least Squares Mean) |
|---|---|
| Hypnotherapy | 10.39 |
At both baseline and end of treatment, patients will be asked to report the number of outpatient visits and procedures they have had within the last 3 months related to their functional dyspepsia symptoms (NCT03884270)
Timeframe: Baseline, 12 weeks
| Intervention | number of events (Median) | |||
|---|---|---|---|---|
| Number of outpatient visits at baseline | Number of outpatient visits at end of treatment | Number of procedures at baseline | Number of procedures at end of treatment | |
| Hypnotherapy | 2 | 1 | 2 | 1 |
At baseline and end of treatment, patients will be asked to report any medications they are taking related to their functional dyspepsia symptoms. (NCT03884270)
Timeframe: Baseline, 12 weeks
| Intervention | number of medications (Median) | |
|---|---|---|
| Medications taking at baseline | Medications taking at end of treatment | |
| Hypnotherapy | 1 | 1 |
"At the end of treatment, patients were asked an open-ended question to obtain feedback on their experience using the web-based platform for treatment. They were asked to rate their difficulty using the web platform on a 7-point scale from Extremely difficult to Extremely easy." (NCT03884270)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Extremely easy | Moderately easy | Somewhat easy | Neutral | Somewhat difficult | Moderately difficult | Extremely difficult | |
| Hypnotherapy | 17 | 3 | 1 | 1 | 0 | 0 | 0 |
"Treatment satisfaction will be assessed with a single item at the end of treatment asking how satisfied they were overall with their assigned treatment (on a 7-point scale from Extremely dissatisfied to Extremely satisfied)" (NCT03884270)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Extremely dissatisfied | Very dissatisfied | Somewhat dissatisfied | Neutral | Somewhat satisfied | Very satisfied | Extremely satisfied | |
| Hypnotherapy | 1 | 0 | 0 | 2 | 12 | 4 | 3 |
35 reviews available for cisapride and Indigestion
| Article | Year |
|---|---|
Do prokinetic agents provide symptom relief through acceleration of gastric emptying? An update and revision of the existing evidence.
Topics: Cisapride; Dyspepsia; Gastric Emptying; Gastrointestinal Agents; Gastroparesis; Humans | 2023 |
Comparative Efficacy of Various Pharmacological Interventions in the Treatment of Functional Dyspepsia: A Network Meta-Analysis.
Topics: Cisapride; Comparative Effectiveness Research; Dyspepsia; Gastrointestinal Agents; Humans; Network M | 2022 |
Prokinetics for functional dyspepsia.
Topics: Benzamides; Benzyl Compounds; Cisapride; Domperidone; Dyspepsia; Erythromycin; Gastrointestinal Agen | 2018 |
Effects of Promotility Agents on Gastric Emptying and Symptoms: A Systematic Review and Meta-analysis.
Topics: Breath Tests; Cisapride; Domperidone; Dopamine D2 Receptor Antagonists; Dyspepsia; Gastric Emptying; | 2019 |
Acupuncture for functional dyspepsia.
Topics: Acupuncture Therapy; Benzamides; Benzyl Compounds; Cisapride; Domperidone; Dyspepsia; Electroacupunc | 2014 |
[Management of gastroparesis and functional dyspepsia after cisapride withdrawal].
Topics: Cisapride; Dyspepsia; Gastrointestinal Agents; Gastroparesis; Humans; Kinetics; Patient Selection; S | 2012 |
Update on the role of drug therapy in non-ulcer dyspepsia.
Topics: Anti-Ulcer Agents; Antidepressive Agents, Tricyclic; Cisapride; Dopamine Antagonists; Dyspepsia; Gas | 2003 |
Systematic review: Antacids, H2-receptor antagonists, prokinetics, bismuth and sucralfate therapy for non-ulcer dyspepsia.
Topics: Administration, Oral; Antacids; Bismuth; Cisapride; Drug Therapy, Combination; Dyspepsia; Gastrointe | 2003 |
[The efficacy of a combination herbal medicine in the treatment of functional dyspepsia. Meta-analysis of randomized double-blind studies on the basis of a valid gastrointestinal symptom profile].
Topics: Adult; Anti-Ulcer Agents; Cisapride; Drug Therapy, Combination; Dyspepsia; Female; Humans; Male; Mid | 2004 |
Phytotherapy for functional dyspepsia: a review of the clinical evidence for the herbal preparation STW 5.
Topics: Antiemetics; Cisapride; Cohort Studies; Double-Blind Method; Dyspepsia; Gastrointestinal Agents; Hum | 2006 |
Meta-analysis of the effects of prokinetic agents in patients with functional dyspepsia.
Topics: Benzamides; Benzyl Compounds; Cisapride; Domperidone; Dopamine Antagonists; Dyspepsia; Gastrointesti | 2007 |
Treatment of functional dyspepsia with serotonin agonists: a meta-analysis of randomized controlled trials.
Topics: Benzamides; Cisapride; Data Interpretation, Statistical; Dopamine Antagonists; Dyspepsia; Gastrointe | 2007 |
[Current concepts concerning functional dyspepsia syndrome].
Topics: Antacids; Anti-Ulcer Agents; Cisapride; Diagnosis, Differential; Dopamine Antagonists; Dyspepsia; Hi | 1995 |
Functional dyspepsia. Current treatment recommendations.
Topics: Cisapride; Dopamine Antagonists; Dyspepsia; Gastric Acid; Gastrointestinal Agents; Gastrointestinal | 1993 |
Cisapride: a gastrointestinal prokinetic drug.
Topics: Adult; Anti-Ulcer Agents; Cisapride; Clinical Trials as Topic; Constipation; Double-Blind Method; Dy | 1994 |
Modern management of dyspepsia.
Topics: Adult; Aged; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Bismuth; Child; C | 1996 |
[Pharmacologic and clinical differentiation of prokinetic drugs].
Topics: Adult; Antiemetics; Child; Cisapride; Clinical Trials as Topic; Domperidone; Dopamine Antagonists; D | 1996 |
Management guidelines for uninvestigated and functional dyspepsia in the Asia-Pacific region: First Asian Pacific Working Party on Functional Dyspepsia.
Topics: Antiemetics; Asia; Cisapride; Disease Management; Domperidone; Dyspepsia; Endoscopy; Gastrointestina | 1998 |
Clinical use of cisapride and its risk-benefit in paediatric patients.
Topics: Child; Child, Preschool; Cisapride; Constipation; Cystic Fibrosis; Drug Interactions; Dyspepsia; Fec | 1998 |
Today's therapy of functional gastrointestinal disorders--does it help?
Topics: Antacids; Benzyl Compounds; Cisapride; Clinical Trials as Topic; Colonic Diseases, Functional; Dyspe | 1998 |
Cisapride: limited access and alternatives.
Topics: Anti-Ulcer Agents; Arrhythmias, Cardiac; Cisapride; Drug and Narcotic Control; Dyspepsia; Female; Ga | 2000 |
[Treatment of severely delayed gastric emptying].
Topics: Cisapride; Diagnosis, Differential; Digestive System Surgical Procedures; Domperidone; Dyspepsia; El | 2000 |
Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis.
Topics: Cisapride; Domperidone; Dopamine Antagonists; Dyspepsia; Gastrointestinal Agents; Humans; Odds Ratio | 2001 |
Treatment of non-ulcer dyspepsia: a meta-analysis of placebo-controlled prospective studies.
Topics: Cimetidine; Cisapride; Domperidone; Dyspepsia; Gastrointestinal Agents; Histamine H2 Antagonists; Hu | 2001 |
H(2) receptor antagonists and prokinetics in dyspepsia: a critical review.
Topics: Cisapride; Double-Blind Method; Dyspepsia; Gastrointestinal Agents; Histamine H2 Antagonists; Humans | 2002 |
[Prokinetics of gastrointestinal system; its newer aspects with regard to motillity stimulants].
Topics: Acetylcholine; Benzamides; Cisapride; Domperidone; Dyspepsia; Gastrointestinal Agents; Gastrointesti | 2002 |
[Disorders of gastric emptying].
Topics: Cisapride; Diabetes Complications; Domperidone; Dyspepsia; Gastric Emptying; Gastroesophageal Reflux | 1992 |
Motility-like dyspepsia. Current concepts in pathogenesis, investigation and management.
Topics: Cisapride; Dyspepsia; Gastric Emptying; Gastrointestinal Agents; Gastrointestinal Motility; Humans; | 1992 |
Cisapride--more selective than metoclopramide.
Topics: Cisapride; Dyspepsia; Gastroesophageal Reflux; Gastrointestinal Motility; Humans; Metoclopramide; Pi | 1990 |
[Therapy of non-ulcer dyspepsia].
Topics: Animals; Anti-Ulcer Agents; Antiemetics; Benzamides; Cisapride; Domperidone; Dyspepsia; Humans; Meto | 1990 |
[Antro-duodenal coordination: definition, effect of prokinetics and possible relationship to non-ulcer dyspepsia].
Topics: Cisapride; Duodenum; Dyspepsia; Gastrointestinal Motility; Humans; Metoclopramide; Piperidines; Pylo | 1990 |
Dose-finding of cisapride in non-ulcer dyspepsia.
Topics: Cisapride; Dose-Response Relationship, Drug; Double-Blind Method; Dyspepsia; Humans; Multicenter Stu | 1990 |
[Cisapride: pharmacology, current therapeutic results and future prospects].
Topics: Cisapride; Constipation; Dyspepsia; Esophagitis; Esophagus; Forecasting; Gastric Emptying; Gastroeso | 1989 |
The effects of cisapride on antroduodenal co-ordination and gastric emptying.
Topics: Cisapride; Dyspepsia; Gastric Emptying; Gastrointestinal Motility; Humans; Piperidines; Postoperativ | 1989 |
Efficacy of cisapride in the treatment of epigastric pain and concomitant symptoms in non-ulcer dyspepsia.
Topics: Cisapride; Clinical Trials as Topic; Double-Blind Method; Dyspepsia; Humans; Piperidines; Serotonin | 1989 |
66 trials available for cisapride and Indigestion
| Article | Year |
|---|---|
Long-term cisapride treatment improves diabetic gastroparesis but not glycaemic control.
Topics: Aged; Blood Glucose; Breath Tests; Cisapride; Diabetes Mellitus, Type 1; Diabetic Neuropathies; Drug | 2002 |
A randomized placebo-controlled trial of simethicone and cisapride for the treatment of patients with functional dyspepsia.
Topics: Adult; Aged; Cisapride; Double-Blind Method; Dyspepsia; Female; Gastrointestinal Agents; Health Stat | 2002 |
Assessment of meal induced gastric accommodation by a satiety drinking test in health and in severe functional dyspepsia.
Topics: Adult; Analysis of Variance; Case-Control Studies; Cisapride; Cross-Over Studies; Double-Blind Metho | 2003 |
Levosulpiride and cisapride in the treatment of dysmotility-like functional dyspepsia: a randomized, double-masked trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Cisapride; Dose-Response Relationship, Drug; Double-B | 2004 |
A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in helicobacter pylori negative, primary care patients with dyspepsia: the CADET-HN Study.
Topics: Adult; Aged; Cisapride; Cost-Benefit Analysis; Drug Costs; Dyspepsia; Female; Gastrointestinal Agent | 2005 |
Lack of effect of Helicobacter pylori on symptom improvement with a prokinetic medication, cisapride, in patients with non-ulcer dyspepsia.
Topics: Adult; Cholinergic Agonists; Cisapride; Drug Administration Schedule; Dyspepsia; Female; Gastric Emp | 2005 |
Prokinetic effect of gut-oriented hypnosis on gastric emptying.
Topics: Adult; Analysis of Variance; Case-Control Studies; Cisapride; Dyspepsia; Gastric Emptying; Gastroint | 2006 |
Helicobacter pylori eradication versus prokinetics in the treatment of functional dyspepsia: a randomized, double-blind study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Cisapride; Clari | 2006 |
A double-blind, randomized, placebo-controlled trial of cisapride in Saudi Arabs with functional dyspepsia.
Topics: Adult; Aged; Anti-Ulcer Agents; Cisapride; Double-Blind Method; Drug Administration Schedule; Dyspep | 1995 |
Efficacy of cisapride therapy in functional dyspepsia.
Topics: Adult; Anti-Ulcer Agents; Cisapride; Double-Blind Method; Dyspepsia; Eructation; Female; Gastric Emp | 1995 |
Cisapride compared with ranitidine in the treatment of functional dyspepsia.
Topics: Adult; Antacids; Anti-Ulcer Agents; Cisapride; Double-Blind Method; Dyspepsia; Eructation; Female; F | 1995 |
[A controlled multi-centre clinical trial on cisapride in treatment of functional dyspepsia].
Topics: Abdominal Pain; Adolescent; Adult; Aged; Cisapride; Diarrhea; Dyspepsia; Female; Humans; Male; Middl | 1995 |
Cisapride or cimetidine in the treatment of functional dyspepsia. Results of a double-blind, randomized, Swiss multicentre study.
Topics: Adult; Cimetidine; Cisapride; Double-Blind Method; Dyspepsia; Female; Humans; Male; Piperidines; Tre | 1994 |
Cisapride versus metoclopramide in the treatment of functional dyspepsia. A double-blind comparative trial.
Topics: Adult; Aged; Anti-Ulcer Agents; Cisapride; Double-Blind Method; Dyspepsia; Female; Humans; Male; Met | 1994 |
Two different dose regimens of cisapride in the treatment of reflux oesophagitis: a double-blind comparison with ranitidine.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aluminum Hydroxide; Antacids; Cisapride; Double-Blind Me | 1993 |
[Efficacy and tolerability of cisapride in a new formula of 10 mg effervescent capsules for the treatment of functional dyspepsia].
Topics: Adult; Aged; Aged, 80 and over; Capsules; Cisapride; Dose-Response Relationship, Drug; Double-Blind | 1993 |
Are routine duodenal and antral biopsies useful in the management of "functional" dyspepsia? A diagnostic and therapeutic study.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Bismuth; Cisapride; Double-Blind Method; Du | 1993 |
A double-blind fluoroscopic study of cisapride on gastrointestinal motility in patients with functional dyspepsia.
Topics: Barium Sulfate; Cisapride; Double-Blind Method; Dyspepsia; Fluoroscopy; Gastric Emptying; Gastrointe | 1993 |
Cisapride in chronic dyspepsia: results of a double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Chronic Disease; Cisapride; Double-Blind Method; Dyspepsia; Female; Gastrointesti | 1993 |
Factors affecting short- and long-term outcome of a short therapeutic trial with cisapride in dyspeptic patients.
Topics: Adult; Age Factors; Aged; Cisapride; Dyspepsia; Female; Follow-Up Studies; Gastrointestinal Motility | 1993 |
Efficacy of cisapride in functional dyspepsia resistant to domperidone or metoclopramide: a double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Chronic Disease; Cisapride; Domperidone; Double-Blind Method; Dyspepsia; Fe | 1993 |
Cisapride in functional dyspepsia: a double-blind, placebo-controlled randomized trial in general practice patients.
Topics: Abdominal Pain; Adult; Aged; Chronic Disease; Cisapride; Double-Blind Method; Dyspepsia; Family Prac | 1993 |
Ultrasound measurement of gastric emptying time in patients with cystic fibrosis and effect of ranitidine on delayed gastric emptying.
Topics: Adolescent; Child; Child, Preschool; Cisapride; Cystic Fibrosis; Dyspepsia; Female; Gastric Emptying | 1996 |
Gastric antral motility in functional dyspepsia. Effect of mental stress and cisapride.
Topics: Cisapride; Cross-Over Studies; Double-Blind Method; Dyspepsia; Female; Gastrointestinal Motility; Hu | 1996 |
Factors affecting dose selection and outcome of cisapride treatment for dyspepsia in primary care. The Austro-Cis Study Group.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Child; Child, Preschool; Cisapride; D | 1996 |
Cisapride in functional dyspepsia in general practice. A placebo-controlled, randomized, double-blind study.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Cisapride; Diagnosis, Differential; Double-Blind Method; | 1997 |
Effect of cisapride on functional dyspepsia in patients with and without histological gastritis: a double-blind placebo-controlled trial.
Topics: Adult; Anti-Ulcer Agents; Cisapride; Double-Blind Method; Dyspepsia; Female; Gastric Mucosa; Gastrit | 1997 |
A double-blind randomized study of cisapride in the treatment of nonulcer dyspepsia. The Canadian Cisapride Nud Study Group.
Topics: Administration, Oral; Adult; Analysis of Variance; Anti-Ulcer Agents; Cisapride; Dose-Response Relat | 1997 |
The Omega-Project--a comparison of two diagnostic strategies for risk- and cost-oriented management of dyspepsia.
Topics: Adult; Cisapride; Costs and Cost Analysis; Domperidone; Dopamine Antagonists; Double-Blind Method; D | 1997 |
Study with two prokinetics in functional dyspepsia and GORD: domperidone vs. cisapride.
Topics: Adult; Anti-Ulcer Agents; Cisapride; Domperidone; Double-Blind Method; Dyspepsia; Female; Follow-Up | 1997 |
Effect of mental stress and cisapride on autonomic nerve functions in functional dyspepsia.
Topics: Adult; Autonomic Pathways; Cisapride; Cross-Over Studies; Double-Blind Method; Dyspepsia; Female; He | 1998 |
Placebo-controlled trial of cisapride and nizatidine in unselected patients with functional dyspepsia.
Topics: Adult; Anti-Ulcer Agents; Cisapride; Double-Blind Method; Dyspepsia; Female; Follow-Up Studies; Huma | 1998 |
The effect of cisapride on dyspepsia symptoms and the electrogastrogram in patients with non-ulcer dyspepsia.
Topics: Adult; Cisapride; Dyspepsia; Electromyography; Gastric Emptying; Gastrointestinal Agents; Humans; Po | 1998 |
The influence of cisapride on gastric tone and the perception of gastric distension.
Topics: Adult; Cisapride; Dyspepsia; Female; Gastric Emptying; Gastric Fundus; Gastrointestinal Agents; Huma | 1998 |
The effect of cisapride on dysmotility-like functional dyspepsia: reduction of the fasting and postprandial area, but not of the postprandial antral expansion.
Topics: Adolescent; Adult; Aged; Cisapride; Double-Blind Method; Dyspepsia; Fasting; Female; Gastrointestina | 1998 |
Observation on frequency spectrum of electrogastrogram (EGG) in acupuncture treatment of functional dyspepsia.
Topics: Acupuncture Therapy; Adult; Cisapride; Dyspepsia; Electrophysiology; Female; Gastritis; Gastrointest | 1998 |
Randomised double-blind comparison of simethicone with cisapride in functional dyspepsia.
Topics: Cisapride; Double-Blind Method; Dyspepsia; Female; Gastrointestinal Agents; Helicobacter pylori; Hum | 1999 |
Treatment of functional dyspepsia with a fixed peppermint oil and caraway oil combination preparation as compared to cisapride. A multicenter, reference-controlled double-blind equivalence study.
Topics: Cisapride; Double-Blind Method; Drug Combinations; Dyspepsia; Female; Gastrointestinal Agents; Helic | 1999 |
Comparative effects of levosulpiride and cisapride on gastric emptying and symptoms in patients with functional dyspepsia and gastroparesis.
Topics: Activities of Daily Living; Administration, Oral; Adult; Aged; Anti-Ulcer Agents; Cisapride; Cross-O | 2000 |
Cisapride provides symptomatic relief in functional dyspepsia associated with gastric myoelectrical abnormality.
Topics: Adult; Aged; Cisapride; Dyspepsia; Electromyography; Electrophysiology; Female; Gastrointestinal Age | 2000 |
Treatment of uninvestigated dyspepsia with cisapride for patients with negative Helicobacter pylori serologies.
Topics: Administration, Oral; Adult; Antibodies, Bacterial; Cisapride; Diagnosis, Differential; Dyspepsia; F | 2000 |
[The effect of prokinetic treatment and eradication of Helicobacter pylori on gastric emptying and symptoms of functional dyspepsia].
Topics: Adolescent; Adult; Cisapride; Drug Therapy, Combination; Dyspepsia; Famotidine; Female; Gastric Empt | 2001 |
A randomised controlled trial of four management strategies for dyspepsia: relationships between symptom subgroups and strategy outcome.
Topics: Anti-Ulcer Agents; Cimetidine; Cisapride; Clinical Protocols; Dyspepsia; Endoscopy, Gastrointestinal | 2001 |
Dyspepsia in primary care: acid suppression as effective as prokinetic therapy. A randomized clinical trial.
Topics: Adult; Cisapride; Cohort Studies; Double-Blind Method; Dyspepsia; Female; Follow-Up Studies; Gastroi | 2001 |
A randomised clinical trial comparing the efficacy of a herbal preparation STW 5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia.
Topics: Adult; Aged; Cisapride; Double-Blind Method; Dyspepsia; Female; Gastroparesis; Humans; Male; Middle | 2002 |
Cisapride treatment of patients with non-ulcer dyspepsia and erosive prepyloric changes. A double-blind, placebo-controlled trial.
Topics: Adult; Cisapride; Confidence Intervals; Double-Blind Method; Dyspepsia; Female; Gastric Mucosa; Huma | 1992 |
Wide gastric antrum in patients with non-ulcer dyspepsia. Effect of cisapride.
Topics: Adolescent; Adult; Aged; Cisapride; Double-Blind Method; Dyspepsia; Fasting; Female; Gastrointestina | 1992 |
Effect of treatment with cisapride alone or in combination with domperidone on gastric emptying and gastrointestinal symptoms in dyspeptic patients.
Topics: Chronic Disease; Cisapride; Domperidone; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; | 1992 |
Gallbladder hypokinesia and normal gastric emptying of liquids in patients with dyspeptic symptoms. A double-blind placebo-controlled clinical trial with cisapride.
Topics: Adult; Cisapride; Double-Blind Method; Dyspepsia; Female; Gallbladder Diseases; Gallbladder Emptying | 1992 |
Clinical efficacy and safety of cisapride and clebopride in the management of chronic functional dyspepsia: a double-blind, randomized study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antiemetics; Benzamides; Chronic Disease; Cisapride; | 1991 |
[Cisapride: clinical experience in 1071 patients with non-ulcer dyspepsia or reflux symptoms].
Topics: Antacids; Cisapride; Dose-Response Relationship, Drug; Dyspepsia; Female; Gastroesophageal Reflux; H | 1991 |
[A retrospective study on the efficacy of the treatment of functional dyspepsia. An evaluation of 166 cases].
Topics: Adult; Antiemetics; Benzamides; Cisapride; Domperidone; Dyspepsia; Female; Humans; Male; Metoclopram | 1991 |
[Treatment of chronic-obstructive upper abdominal complaints. Outlook. Further hypothetical indications].
Topics: Cisapride; Clinical Trials as Topic; Constipation; Dyspepsia; Gastroesophageal Reflux; Gastrointesti | 1990 |
Dose-finding of cisapride in non-ulcer dyspepsia.
Topics: Cisapride; Dose-Response Relationship, Drug; Double-Blind Method; Dyspepsia; Humans; Multicenter Stu | 1990 |
[Cisapride for the treatment of irritable stomach--results of 2 multicenter studies].
Topics: Cisapride; Dose-Response Relationship, Drug; Dyspepsia; Humans; Multicenter Studies as Topic; Piperi | 1990 |
Longterm oral cisapride improves interdigestive antroduodenal motility in dyspeptic patients.
Topics: Administration, Oral; Adult; Cisapride; Digestion; Duodenum; Dyspepsia; Female; Gastrointestinal Mot | 1990 |
Cisapride and gastric emptying of a solid meal in dyspeptic diabetics without autonomic neuropathy and in healthy volunteers.
Topics: Adult; Cisapride; Diabetes Mellitus, Type 1; Dyspepsia; Female; Gastric Emptying; Humans; Male; Midd | 1989 |
Symptomatic, radionuclide and therapeutic assessment of chronic idiopathic dyspepsia. A double-blind placebo-controlled evaluation of cisapride.
Topics: Adult; Chronic Disease; Cisapride; Clinical Trials as Topic; Double-Blind Method; Dyspepsia; Female; | 1989 |
Relief of epigastric pain in nonulcer dyspepsia: controlled trial of the promotility drug cisapride.
Topics: Adult; Antacids; Cisapride; Clinical Trials as Topic; Double-Blind Method; Dyspepsia; Female; Humans | 1989 |
Efficacy of cisapride in the treatment of epigastric pain and concomitant symptoms in non-ulcer dyspepsia.
Topics: Cisapride; Clinical Trials as Topic; Double-Blind Method; Dyspepsia; Humans; Piperidines; Serotonin | 1989 |
Cisapride stimulates antral motility and decreases biliary reflux in patients with severe dyspepsia.
Topics: Adult; Aged; Bile Acids and Salts; Cisapride; Double-Blind Method; Duodenogastric Reflux; Dyspepsia; | 1989 |
Cisapride in the management of chronic functional dyspepsia: a multicenter, double-blind, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Chronic Disease; Cisapride; Clinical Trials as Topic; Double-Blind Method; | 1987 |
[Treatment of irritated stomach with cisapride. A placebo-controlled double-blind study].
Topics: Cisapride; Clinical Trials as Topic; Double-Blind Method; Dyspepsia; Gastric Emptying; Humans; Piper | 1986 |
Effect of chronic administration of cisapride on gastric emptying of a solid meal and on dyspeptic symptoms in patients with idiopathic gastroparesis.
Topics: Adult; Cisapride; Clinical Trials as Topic; Double-Blind Method; Dyspepsia; Female; Gastric Emptying | 1987 |
Cisapride in non-ulcer dyspepsia. Results of a placebo-controlled trial.
Topics: Cisapride; Clinical Trials as Topic; Double-Blind Method; Dyspepsia; Humans; Peptic Ulcer; Piperidin | 1987 |
Measurement of gastric emptying in dyspeptic patients: effect of a new gastrokinetic agent (cisapride).
Topics: Adult; Aged; Cisapride; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Dyspepsia; F | 1985 |
40 other studies available for cisapride and Indigestion
| Article | Year |
|---|---|
[Rational treatment of patients with functional dyspepsia].
Topics: Antidepressive Agents, Tricyclic; Cisapride; Domperidone; Dyspepsia; Helicobacter Infections; Humans | 2021 |
[Cardiac safety of cinitapride].
Topics: Arrhythmias, Cardiac; Aryl Hydrocarbon Hydroxylases; Benzamides; Cisapride; Cytochrome P-450 CYP2C8; | 2010 |
[Comparative study with prokinetic agents. Dyspepsia can be managed with phytotherapy].
Topics: Cisapride; Clinical Trials as Topic; Dyspepsia; Follow-Up Studies; Gastrointestinal Agents; Humans; | 2002 |
[The effect of Helicobacter pylori eradication on prokinetic treatment on the quality of life in functional dyspepsia].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles | 2004 |
[Electrogastrography monitoring of the effectiveness of prokinetic and cognitive therapy in functional dyspepsia].
Topics: Adult; Cisapride; Cognitive Behavioral Therapy; Dyspepsia; Electromyography; Female; Gastrointestina | 2005 |
An anorexic woman with convulsive loss of consciousness. Syncope or epileptic fits?
Topics: Adult; Anorexia; Cisapride; Diagnosis, Differential; Dyspepsia; Epilepsy; Female; Gastrointestinal A | 2007 |
Influence of cisapride on gastric emptying of solids and liquids monitored by 13C breath tests.
Topics: Acetates; Adult; Anti-Ulcer Agents; Breath Tests; Caprylates; Carbon Isotopes; Cisapride; Dyspepsia; | 1995 |
Gastric emptying and myoelectrical activity in children with nonulcer dyspepsia. Effect of cisapride.
Topics: Adolescent; Child; Child, Preschool; Cisapride; Dyspepsia; Electrophysiology; Female; Gastric Emptyi | 1995 |
[Drug therapy of gastrointestinal motility disorders].
Topics: Cisapride; Domperidone; Dyspepsia; Gastroesophageal Reflux; Gastroparesis; Humans; Metoclopramide; P | 1995 |
A Round Table on Dyspepsia. Proceedings of a symposium. Athens, 30 September 1992.
Topics: Animals; Cisapride; Dyspepsia; Gastrointestinal Motility; Humans; Piperidines | 1993 |
Gastric emptying and bloating in anorexia nervosa.
Topics: Adult; Anorexia Nervosa; Body Image; Body Weight; Cisapride; Dyspepsia; Female; Gastric Emptying; Ho | 1993 |
Functional dyspepsia versus other functional gastrointestinal disorders: a practical approach in Belgian general practices.
Topics: Adult; Aged; Belgium; Cisapride; Cluster Analysis; Constipation; Dyspepsia; Family Practice; Female; | 1993 |
Risk factors, co-medication, and concomitant diseases: their influence on the outcome of therapy with cisapride.
Topics: Cisapride; Drug Therapy, Combination; Dyspepsia; Female; Gastrointestinal Motility; Humans; Male; Mi | 1993 |
Dyspepsia and dyspepsia subgroups in Japan: symptom profiles and experience with cisapride.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Cisapride; Dyspepsia; Female; Gastrointestinal Mo | 1993 |
A German drug-monitoring study in general practice patients receiving cisapride for functional dyspepsia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Cisapride; Drug Monitoring; Dyspepsia; Family Pra | 1993 |
Effect of cisapride therapy for severe dyspepsia on gastrointestinal symptoms and quality of life.
Topics: Adult; Aged; Cisapride; Dyspepsia; Female; Gastrointestinal Motility; Humans; Male; Middle Aged; MMP | 1993 |
Symptom improvement from prokinetic therapy corresponds to improved quality of life in patients with severe dyspepsia.
Topics: Adult; Aged; Attitude to Health; Cisapride; Domperidone; Dyspepsia; Female; Gastrointestinal Agents; | 1996 |
[Management of dyspepsia. Management plan aimed at prevention of upper abdominal complaints].
Topics: Abdominal Pain; Anti-Ulcer Agents; Cisapride; Dyspepsia; Esophagitis, Peptic; Humans; Piperidines | 1996 |
Clinical trials in nonulcer dyspepsia (NUD): a cautionary note. A closer look at "a double-blind randomized study of cisapride in the treatment of nonulcer dyspepsia".
Topics: Anti-Ulcer Agents; Cisapride; Double-Blind Method; Dyspepsia; Humans; Piperidines; Placebo Effect; R | 1997 |
[Possibilities of ultrasonography of gastric emptying].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cisapride; Diabetic Neuropathies; Dyspepsia; Female; Gas | 1996 |
Delayed gastric emptying during interferon-alpha therapy in patients with chronic hepatitis C: relief by cisapride.
Topics: Antiviral Agents; Cisapride; Dyspepsia; Female; Gastric Emptying; Gastrointestinal Agents; Hepatitis | 1997 |
Lack of efficacy of cisapride and nizatidine in dyspepsia.
Topics: Cisapride; Double-Blind Method; Dyspepsia; Family Practice; Gastrointestinal Agents; Histamine H2 An | 1998 |
Update from the Canadian Dyspepsia Working Group.
Topics: Canada; Cisapride; Dyspepsia; Gastroesophageal Reflux; Gastrointestinal Agents; Heart Diseases; Huma | 2000 |
Drug-induced symptoms of functional dyspepsia and nausea. A symmetry analysis of one million prescriptions.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Antiemetics; Cisapride; Databases, Factual; Drug- | 2000 |
[Drug therapy of functional dyspepsia. A review based on Cochrane Reviews].
Topics: Antacids; Cisapride; Databases, Bibliographic; Dyspepsia; Evidence-Based Medicine; Gastrointestinal | 2001 |
Functional dyspepsia in children.
Topics: Adolescent; Anti-Ulcer Agents; Child; Child, Preschool; Cisapride; Diagnosis, Differential; Dyspepsi | 2001 |
A refined method for the meta-analysis of controlled clinical trials with binary outcome.
Topics: Cisapride; Computer Simulation; Dyspepsia; Gastrointestinal Agents; Humans; Meta-Analysis as Topic; | 2001 |
Nutritional implications of chronic dyspepsia in childhood.
Topics: Body Weight; Child; Chronic Disease; Cisapride; Dyspepsia; Female; Gastric Emptying; Humans; Male; N | 2002 |
Treatment of non-ulcer dyspepsia: are prokinetics effective?
Topics: Anti-Ulcer Agents; Cisapride; Dyspepsia; Epidemiologic Research Design; Humans; Outcome Assessment, | 2002 |
Reversal of gastric electrical dysrhythmias by cisapride in children with functional dyspepsia. Report of three cases.
Topics: Child; Child, Preschool; Cisapride; Dyspepsia; Female; Fourier Analysis; Gastric Emptying; Humans; M | 1992 |
[Irritable stomach. Empirical therapy of functional digestive disorders with cisapride--a new trend in practice. Report of a symposium. 1 March 1991, London].
Topics: Cisapride; Dyspepsia; Humans; Piperidines | 1991 |
[Interdigestive migrating complex (IMC) and effect of cisapride in patients with non-ulcer dyspepsia (NUD)].
Topics: Aged; Cisapride; Dyspepsia; Female; Gastrointestinal Motility; Humans; Hydrogen-Ion Concentration; M | 1991 |
Stimulatory effect of N-[4-[2-(dimethylamino)-ethoxy] benzyl]-3,4-dimethoxybenzamide hydrochloride (HSR-803) on normal and delayed gastrointestinal propulsion.
Topics: Acetaminophen; Administration, Oral; Animals; Benzamides; Benzyl Compounds; Cisapride; Dogs; Domperi | 1991 |
[Clinical effects of gastrointestinal-motility stimulating agents on non-ulcer dyspepsia].
Topics: Acetylcholine; Adenosine Triphosphate; Adult; Cisapride; Domperidone; Drug Therapy, Combination; Dys | 1990 |
[The typical patient with disorder of digestive motility].
Topics: Cisapride; Dyspepsia; Gastric Emptying; Gastroesophageal Reflux; Humans; Intestinal Pseudo-Obstructi | 1990 |
[A drive substance for the motor in digestion. Introduction].
Topics: Acetylcholine; Cisapride; Dyspepsia; Gastric Emptying; Gastroesophageal Reflux; Gastrointestinal Mot | 1990 |
[Encouragement for the tired stomach. Cisapride, a specific pro-kinetic drug for upset stomach].
Topics: Acetylcholine; Cisapride; Dose-Response Relationship, Drug; Dyspepsia; Gastric Emptying; Gastroesoph | 1990 |
Cisapride for severe non-ulcer dyspepsia, pseudoobstruction and constipation.
Topics: Adult; Aged; Cisapride; Constipation; Dyspepsia; Female; Humans; Intestinal Pseudo-Obstruction; Male | 1989 |
Effect of cisapride on gastric emptying in dyspeptic patients.
Topics: Adult; Cisapride; Dyspepsia; Female; Gastric Emptying; Humans; Indium Radioisotopes; Male; Middle Ag | 1988 |
[Clinical experience with a new pharmaceutical formulation of cisapride in patients with functional dyspepsia].
Topics: Adult; Aged; Cisapride; Dyspepsia; Female; Humans; Male; Middle Aged; Piperidines; Powders | 1987 |